Skripsi
GAMBARAN RERATA KADAR HEMOGLOBIN PASIEN TB RESISTAN OBAT DENGAN PENGOBATAN REGIMEN JANGKA PANJANG DI RSUP DR. MOHAMMAD HOESIN PALEMBANG PADA TAHUN 2022
Background: Based on the World Health Organization (WHO) 2023 report, there were 7.5 million new cases of TB worldwide in 2022, of which 410,000 were drug-resistant TB. The duration and the many drugs consumed in dealing with drug-resistant TB, make the adverse effect of treatment higher. One of the most frequent complications is a decrease in Hb levels below normal. Anemia in drug-resistant TB patients is caused by several reasons such as: side effects of long-term treatment, namely linezolid, iron deficiency, and chronic inflammation. The purpose of this study is to determine the average hemoglobin levels in the 0th month, 1st month, 3rd month, and 5th month of treatment in Drug-resistant TB Patients who received long-term regimen treatment at RSMH in 2022. Methods: In this study, the observational descriptive method was used. All data collected for the study came from secondary data from the RSMH Medical Record Installation for the January–December 2022 period. Data are presented in the form of tables and curves. Results: From 34 samples observed, the average Hb levels in the 0th, 1st, 3rd, and 5th months were 12.33 g/dL, 11.58 g/dL, 11.40 g/dL and 12.04 g/dL. Based on red blood cell morphology, patients tend to experience normochromic normocytic anemia. This indicates that the chronic infection of M.tb and the side effects of linezolid treatment are one of the main factors in decreasing Hb levels in Drug Resistant TB Patients who received long-term treatment regimens. Conclusion: Based on this study, the highest average Hb levels were obtained in 0th month, the most significant average decrease was in the 1st month, the lowest average was in the 3rd month, and there was an improvement in average Hb levels in the 5th month.
Inventory Code | Barcode | Call Number | Location | Status |
---|---|---|---|---|
2407000159 | T136807 | T1368072023 | Central Library (Refferens) | Available but not for loan - Not for Loan |
No other version available